| CASE REPORT |
|
| Year : 2022 | Volume
: 5
| Issue : 3 | Page : 107-109 |
|
|
WHO grade III diffuse astrocytic glioma in a 35-year-old male
Rong Du, Huandong Liu, Guoqing Yi, Huilin Cheng, Ping Liang
Department of Neurosurgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province, China
Correspondence Address:
Dr. Ping Liang
Department of Neurosurgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009
China
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/glioma.glioma_26_22
|
|
|
Gliomas are tumors that originate from glial cells and the most common neoplasms in the central nervous system. The World Health Organization (WHO) has classified glioma into four grades, I to IV, with multidisciplinary therapies required for the management of high-grade gliomas (grades III and IV). Molecular pathology has become increasingly critical in guiding the treatment and predicting the prognosis of patients with gliomas. A 35-year-old man diagnosed with WHO grade III diffuse astrocytic glioma initially underwent surgical resection, followed by immunohistochemical and molecular diagnosis. The patient was administered adjuvant radiotherapy and chemotherapy based on the molecular characteristics of the tumor. Long term follow-up showed a relatively satisfactory therapeutic response. Molecular classification may help guide decisions on the comprehensive treatment of patients with WHO grade III diffuse astrocytic glioma. This study was approved by the Ethics Committee of Zhongda Hospital of Southeast University, China (approval No. 20211015001, approval date: October 15, 2021).
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
